Market Overview

Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV Healthcare for $350M Upfront Plus Milestone Payments


Squibb Company (NYSE: BMY) today announced that it has
entered into two individual agreements with ViiV Healthcare, a global
HIV company, to divest its pipeline of investigational HIV medicines
consisting of a number of programs at different stages of discovery,
preclinical and clinical development. Under these agreements, ViiV will
pay to Bristol-Myers Squibb upfront payments totaling $350 million with
potential development and regulatory milestone payments of up to $518
million for the clinical assets and up to $587 million for the discovery
and pre-clinical programs. Once products are approved and
commercialized, ViiV Healthcare will pay tiered royalties. Additionally,
ViiV Healthcare will pay sales-based milestone payments of up to $750
million for each of the clinical assets

See full press release

Posted-In: News Press Releases


Related Articles (BMY + GSK)

View Comments and Join the Discussion!